Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Musical Chairs For Off-Patent Executives In 2021

Hiring Highlights From The Past Year Across The Off-Patent Industry

Executive Summary

Last year was a year of significant executive changes in the off-patent industry, with numerous high-profile hires and departures from companies like Sandoz, Teva, Viatris, Hikma, Fresenius, Neuraxpharm and Stada.

You may also be interested in...



‘No Decision’ On Sandoz As Novartis Continues To Explore Options

Novartis said it had so far made “no decision” as it continues to consider numerous options for Sandoz, from retaining the business to separation, in order to maximize value for shareholders and capitalize upon the growing autonomy of its generics business.

Who’s Hired? Stada Appoints New Biosimilars Head

Stada has welcomed former Novo Nordisk executive Erin Federman into its ranks as she steps into the role of global commercial head of biosimilars. Organizations such as the Association for Accessible Medicines, Granules India, Synthon, Taro and Mayne have also appointed new senior staff members in recent months.

Advanz Appoints Stada Europe Head As New CEO

Stada’s head of Europe, Steffen Wagner, is set to become the new CEO of Advanz early next year, while current CEO Graeme Duncan will step down and take a new role as special advisor to the board. Advanz is also appointing a new chief financial officer, with Merck Healthcare’s Andreas Stickler set to succeed Adeel Ahmad in January.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

GB151539

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel